ストックスクリーナーアプリを入手
33.73
1.78%
-0.61
アフターアワーズ：
33.73
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks - Yahoo Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short Interest - MarketBeat
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold - Nasdaq
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals - GuruFocus.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low on Insider Selling - MarketBeat
Insider Sale: CEO Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277 - Investing.com
Ionis Pharmaceuticals director Joseph Loscalzo sells shares for $511,426 - Investing.com
Ionis Pharmaceuticals CEO Brett Monia sells $252,294 in stock - Investing.com
T. Rowe Price Investment Management, Inc. Expands Stake in Ionis Pharmaceuticals Inc - GuruFocus.com
Piper Sandler Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer - cnhinews.com
Baillie Gifford & Co. Sells 220,673 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by StockNews.com to "Sell" - MarketBeat
What is Leerink Partnrs' Forecast for IONS FY2024 Earnings? - MarketBeat
Wellington Management Group LLP Increases Stake in Ionis Pharmac - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs - MarketBeat
ARK Investment Management LLC Buys 23,244 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus - MSN
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ionis to present at upcoming investor conferences - GuruFocus.com
FDA agrees to review Ionis’ donidalorsen as treatment for HAE - Angioedema News Today
Is there a 2024 Duloxetine recall? FDA flags 7,100+ bottles of generic Cymbalta antidepressants - AOL
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Why Walgreens, CVS and Rite Aid are closing thousands of drug stores across America - AOL
Needham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - AOL
Ionis announces design for Phase III trial of Angelman syndrome therapy - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
Ionis Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Ionis reaches agreement on phase 3 trial design for Angelman candidate - Seeking Alpha
Ionis Pharmaceuticals Beats on Revenue - The Motley Fool
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings: Revenue Surpa - GuruFocus.com
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - The Motley Fool
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Ionis Pharmaceuticals: Q3 Earnings Snapshot - San Antonio Express-News
Ionis gears up for Phase 3 Angelman syndrome trial - Investing.com
Ionis gears up for Phase 3 Angelman syndrome trial By Investing.com - Investing.com UK
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com - MarketBeat
Ionis' donidalorsen awaits FDA decision for HAE treatment - Investing.com India
FDA Sets Goal Date for Donidalorsen in HAE - Managed Healthcare Executive
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
FDA accepts donidalorsen NDA for prophylactic hereditary angioedema - Contemporary Pediatrics
FDA accepts Ionis NDA for donidalorsen - The Pharma Letter
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PR Newswire
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Shareholders in Ionis Pharmaceuticals (NASDAQ:IONS) have lost 32%, as stock drops 4.0% this past week - Simply Wall St
abrdn plc Has $12.06 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):